Processing...
Clinical Trials for Esophageal Cancer
Search
Search
There are 81 active trials for advanced/metastatic esophageal cancer.
Click on a trial to see more information.
81 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including HNSCC, NSCLC, GI, GU, gynecologic, sarcoma, neuroendocrine, and NUT carcinoma—who have measurable disease and good performance status, to evaluate the intravenous BRD4 degrader MT-4561 administered weekly. MT-4561 is a novel agent targeting BRD4 for ubiquitin-mediated degradation and is being assessed primarily for safety and initial efficacy in this biomarker-unselected population.
ClinicalTrials.gov ID: NCT06943521
TrialFetch AI summary: This trial enrolls adults with advanced, FAP-positive solid tumors who have progressed on or lack standard therapy, using [203Pb]Pb-PSV359 SPECT imaging to confirm FAP expression and [212Pb]Pb-PSV359, a FAP-targeted alpha-emitting peptide-radiopharmaceutical, for systemic therapy.
ClinicalTrials.gov ID: NCT06710756
TrialFetch AI summary: Adults with previously treated, unresectable advanced/metastatic solid tumors (NSCLC, HNSCC, ESCC, left‑sided CRC) receive ALX2004 monotherapy, an investigational EGFR‑targeted antibody–drug conjugate carrying a topoisomerase I inhibitor payload designed for bystander effect. Excludes candidates for curative local therapy, rapidly progressive disease, short life expectancy, and prior exposure to topoisomerase I inhibitor ADCs.
ClinicalTrials.gov ID: NCT07085091
TrialFetch AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.
ClinicalTrials.gov ID: NCT07109726
TrialFetch AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.
ClinicalTrials.gov ID: NCT03539822
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic CLDN18.2-positive solid tumors (e.g., gastric/GEJ, pancreatic, esophageal adenocarcinoma, biliary tract cancers) after prior systemic therapy receive BL-M05D1, an IV CLDN18.2-targeting antibody–drug conjugate linking a cathepsin B–cleavable topoisomerase I inhibitor payload, given every 21 days. Key eligibility includes measurable disease, ECOG 0–1, adequate organ function, and prior appropriate targeted/immunotherapy for actionable biomarkers.
ClinicalTrials.gov ID: NCT07021066
TrialFetch AI summary: Adults with unresectable, locally advanced, or metastatic gastric/GEJ/esophageal or pancreatic adenocarcinoma expressing CLDN18.2 (IHC ≥1+ in ≥50%) receive LB1908, an autologous CLDN18.2-directed CAR-T therapy, as monotherapy in second or later lines or as consolidation after disease control on first-line chemotherapy. Key exclusions include prior cellular/gene therapy, significant effusions/bleeding risk, active autoimmune disease requiring immunosuppression, unstable cardiac/infectious disease, and active CNS disease (except stable treated brain mets in monotherapy cohorts).
ClinicalTrials.gov ID: NCT05539430
TrialFetch AI summary: Adults with CLDN18.2-positive advanced/metastatic gastric, GEJ, esophageal, or pancreatic adenocarcinoma after prior systemic therapy receive AZD5863 monotherapy, a CLDN18.2×CD3 T cell–engaging bispecific antibody, via IV or SC administration. Trial focuses on dose finding and preliminary efficacy with RECIST-measurable disease and ECOG 0–1 required.
ClinicalTrials.gov ID: NCT06005493
TrialFetch AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.
ClinicalTrials.gov ID: NCT07001592
TrialFetch AI summary: Adults with metastatic/unresectable solid tumors after standard therapy, with dose expansion in squamous histologies (sqNSCLC with/without NRF2 or CUL3 mutations, HNSCC, ESCC post–platinum and checkpoint inhibitor), receive the investigational KEAP1 activator VVD-130037 orally as monotherapy or combined with docetaxel or paclitaxel. VVD-130037 is a covalent, allosteric molecular glue that enhances KEAP1–CUL3–mediated NRF2 degradation to counter NRF2-driven oncogenesis and taxane resistance; patients with KEAP1 nonsense/frameshift mutations are excluded.
ClinicalTrials.gov ID: NCT05954312